Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
enVVeno Medical Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NVNO
Nasdaq
8731
https://envveno.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for enVVeno Medical Corp
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
- Apr 24th, 2024 10:15 am
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
- Apr 16th, 2024 1:00 pm
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
- Apr 9th, 2024 12:45 pm
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
- Mar 15th, 2024 1:00 pm
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
- Mar 6th, 2024 1:40 pm
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
- Mar 3rd, 2024 12:01 pm
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Feb 29th, 2024 9:15 pm
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
- Feb 20th, 2024 1:30 pm
enVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability
- Jan 6th, 2024 1:29 pm
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
- Dec 14th, 2023 4:30 pm
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
- Nov 16th, 2023 1:45 pm
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Oct 26th, 2023 12:05 pm
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference
- Oct 12th, 2023 1:00 pm
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
- Oct 6th, 2023 12:57 pm
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve
- Oct 6th, 2023 12:56 pm
enVVeno Medical Announces Private Placement of $28 Million
- Oct 6th, 2023 12:55 pm
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Jul 31st, 2023 8:45 pm
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
- Jul 14th, 2023 12:05 pm
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
- Jul 5th, 2023 12:05 pm
enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update
- May 1st, 2023 12:00 pm
Scroll